Neurocrine Bioscienc (NQ: NBIX )
Price and Volume
Detailed QuoteVolume | 139 |
Open | 139.44 |
Bid (Size) | 139.32 (1) |
Ask (Size) | 142.98 (2) |
Prev. Close | 139.44 |
Today's Range | 139.44 - 139.44 |
52wk Range | 89.04 - 143.35 |
Shares Outstanding | 98,700,000 |
Dividend Yield | N/A |
Top News
More NewsPerformance
More News
Read More
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
March 15, 2024
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
March 13, 2024
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
February 08, 2024
Earnings Scheduled For February 7, 2024
February 07, 2024
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
February 16, 2024
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
February 07, 2024
Earnings Outlook For Neurocrine Biosciences
February 06, 2024
Unveiling 13 Analyst Insights On Neurocrine Biosciences
January 23, 2024
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
NASDAQ:NBIX, a growth stock which is not overvalued.
January 15, 2024
NASDAQ:NBIX is not too expensive for the growth it is showing.
February 06, 2024
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.